<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id>
      <journal-title-group>
        <journal-title>BMC Cancer</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2407</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25249211</article-id>
      <article-id pub-id-type="pmc">4190344</article-id>
      <article-id pub-id-type="publisher-id">4895</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2407-14-701</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Campos-G&#xF3;mez</surname>
            <given-names>Sa&#xFA;l</given-names>
          </name>
          <address>
            <email>saulcampos@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff11"/>
          <xref ref-type="aff" rid="Aff12"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Flores-Arredondo</surname>
            <given-names>Jose H</given-names>
          </name>
          <address>
            <email>josehfloresa@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff13"/>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dorantes-Heredia</surname>
            <given-names>Rita</given-names>
          </name>
          <address>
            <email>ritadorantesh@yahoo.com.mx</email>
          </address>
          <xref ref-type="aff" rid="Aff15"/>
          <xref ref-type="aff" rid="Aff16"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chapa-Ibarg&#xFC;engoitia</surname>
            <given-names>M&#xF3;nica</given-names>
          </name>
          <address>
            <email>monicachapaibar@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff17"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de la Pe&#xF1;a-Lopez</surname>
            <given-names>Roberto</given-names>
          </name>
          <address>
            <email>rdelap70@yahoo.com.mx</email>
          </address>
          <xref ref-type="aff" rid="Aff12"/>
          <xref ref-type="aff" rid="Aff16"/>
        </contrib>
        <aff id="Aff11"><label/>Departamento de Oncolog&#xED;a M&#xE9;dica, Centro Oncol&#xF3;gico Estatal, ISSEMYM, Toluca, M&#xE9;xico </aff>
        <aff id="Aff12"><label/>Departamento de Oncolog&#xED;a y Hematolog&#xED;a, Instituto Nacional de Ciencias M&#xE9;dicas y Nutrici&#xF3;n Salvador Zubir&#xE1;n (INCMNSZ), M&#xE9;xico City, M&#xE9;xico </aff>
        <aff id="Aff13"><label/>The Methodist Hospital Research Institute, The Methodist Hospital at Houston, Houston, Texas USA </aff>
        <aff id="Aff14"><label/>Department of Internal Medicine, Baylor College of Medicine, Houston, Texas USA </aff>
        <aff id="Aff15"><label/>Departamento de Patolog&#xED;a, Instituto Nacional de Ciencias M&#xE9;dicas y Nutrici&#xF3;n Salvador Zubir&#xE1;n (INCMNSZ), M&#xE9;xico City, M&#xE9;xico </aff>
        <aff id="Aff16"><label/>Fundaci&#xF3;n Cl&#xED;nica M&#xE9;dica Sur, M&#xE9;xico City, M&#xE9;xico </aff>
        <aff id="Aff17"><label/>Departamento de Radiolog&#xED;a e Im&#xE1;gen, Instituto Nacional de Ciencias M&#xE9;dicas y Nutrici&#xF3;n Salvador Zubir&#xE1;n (INCMNSZ), M&#xE9;xico City, M&#xE9;xico </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>23</day>
        <month>9</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>14</volume>
      <elocation-id>701</elocation-id>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>1</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>8</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Campos-G&#xF3;mez et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Ductal carcinomas of the parotid gland are rare, highly aggressive, have a poor prognosis and are histologically similar to Ductal Breast Cancer. We report what we believe to be the first case in literature of metastatic salivary duct carcinoma (SDC) of the parotid gland with objective response to tamoxifen and aromatase inhibitors, achieving a long-term stability of disease with no associated toxicity.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 70-year-old female was referred to our institution for treatment of a painless nodular lesion in the scalp, localized in the frontal region of the cranium. A biopsy was taken and tested positive for metastatic ductal carcinoma. On PET CT hypermetabolic nodules were localized in the left parotid gland (11&#xA0;mm), right parotid gland (10 and 12&#xA0;mm), submandibular node (11&#xA0;mm) and left cervical node (10&#xA0;mm). A salivary ductal carcinoma was considered to be the primary tumor. The patient was subsequently started on tamoxifen, with a complete response from the scalp nodule and left parotid nodule, while the right parotid nodule demonstrated a partial response that maintained stable for 2&#xA0;years until progression. Anastrazol was chosen as the next line of treatment, achieving 6 more months of stable disease. As a pseudo-adjuvant treatment, surgical resection of the right parotid lesion was performed and helped achieve two years of disease stability.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Estrogen receptor antagonists such as tamoxifen or aromatase inhibitors may represent a target for the establishment of a safe alternative and novel therapy for SDC, however more accurate data obtained from larger studies are required.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Tamoxifen</kwd>
        <kwd>Salivary gland</kwd>
        <kwd>Ductal carcinoma</kwd>
        <kwd>Estrogen receptor antagonist</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Ductal carcinomas of the parotid gland are rare, highly aggressive, have a poor prognosis and are histologically similar to Ductal Breast Cancer. Salivary gland tumors metastasize most frequently to lymph nodes, lung, liver and bones. Distant metastases occur in 27%, independent of histology and 46% in adenoid cyst cell types and high-grade salivary ductal carcinoma
[<xref ref-type="bibr" rid="CR1">1</xref>]. Surgical resection of solitary metastasis may be considered in select cases, but the goal of chemotherapy in metastatic or recurrent disease is palliative care, based on response rates that range from 10-30% and the lack of evidence benefiting survival
[<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>Salivary ductal carcinomas are an uncommon and high-grade adenocarcinoma arising from the ductal epithelium, which Kleinsasser et al. reported in 1968 for the first time
[<xref ref-type="bibr" rid="CR3">3</xref>], and the World Health Organization classified as a distinct neoplasm in 1991
[<xref ref-type="bibr" rid="CR4">4</xref>]. Ductal carcinomas, typically present in the sixth or seventh decade of life and are more prevalent in males (3:1.8)
[<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The parotid gland is involved in 80% of diagnosis, followed by the submandibular gland in 8% and the rest in the minor salivary glands
[<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The aggressive behavior characterizing ductal carcinomas is associated with rapid progression, early lymph node metastasis, a high risk of local recurrence, distant metastasis and ultimately a low survival rate, 3&#xA0;yrs. median
[<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p>
      <p>Due to SDC&#x2019;s histological similarity to ductal carcinoma of the breast, hormonal receptor status and regulation has been a subject of interest. However, hormone receptor expression is virtually absent in most malignant salivary gland tumors, with the exception of the androgen receptor, which is present in approximately 92% of cases. Similar to invasive ductal carcinoma of the breast, overexpression and amplification of the HER-2 gene is present in SDC. Patients with SDC and HER-2 overexpression and amplification may be targeted with trastuzumab and obtain positive responses to therapy
[<xref ref-type="bibr" rid="CR8">8</xref>]. SDC in comparison to ductal carcinoma of the breast expresses in a lower percentage estrogen (&#x2212;8%) or progesterone receptors
[<xref ref-type="bibr" rid="CR9">9</xref>]. Androgen receptor (AR) therapy however has emerged as a possible target, due to the fact that a majority of SDC lesions express AR and have demonstrated clinical benefit
[<xref ref-type="bibr" rid="CR10">10</xref>].</p>
      <p>Cytotoxic chemotherapy has limited benefit in a subtype of SDC that is rare and aggressive, for which genotyping analysis has been pursued to help identify novel tumor-specific mutations that may help direct targeted therapies in these cases. There has been an interest in recently discovered PIK3CA, PTEN and BRAF V600E kinase mutations in subsets of HER2-negative SDC; due to these recent discoveries the aforementioned pathways have been suggested as therapeutic targets
[<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p>
      <p>The following case report is what we believe to be the first case in literature of metastatic salivary duct carcinoma of the parotid gland with objective response to tamoxifen and aromatase inhibitors, achieving a long-term stability of disease with no associated toxicity.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 70-year-old female was referred for treatment of a painless nodular lesion with a diameter of 2&#xA0;cm in the scalp, localized in the frontal region of the cranium. Her past medical history was unremarkable. A biopsy was taken and tested positive for metastatic ductal carcinoma. Further analysis revealed Estrogen Receptor positivity. Mastrography and CT did not demonstrate any evidence of a primary tumor, while PET CT showed hypermetabolic nodules localized as follows: 11&#xA0;mm in the left parotid gland, 10 and 12&#xA0;mm in the right parotid gland, 11&#xA0;mm submandibular node and 10&#xA0;mm left cervical node. At this point, there was clinical suspicion of a primary salivary ductal carcinoma. The patient was started on tamoxifen, 20&#xA0;mg daily, with a complete response in the scalp nodule and left parotid nodule, although a partial response was observed on the right parotid lesions (Figure&#xA0;
<xref rid="Fig1" ref-type="fig">1</xref>B). The patient continued stable for two years, after which progression of the right parotid nodule was observed through clinical palpation and through CT as a lesion 2 cms in diameter located in the right periaricular area (Figure&#xA0;
<xref rid="Fig1" ref-type="fig">1</xref>C), without cranial nerve involvement or palpable cervical lymphadenopathy. There was no evidence of any metastatic lesions. Anastrozole 1&#xA0;mg/day was started, achieving stable disease within 8&#xA0;months of treatment (Figure&#xA0;
<xref rid="Fig1" ref-type="fig">1</xref>D). Local control of the parotid lesion was obtained via surgical resection (Figure&#xA0;
<xref rid="Fig1" ref-type="fig">1</xref>E), tissue was sent to pathology, where a Hematoxylin and Eosin (H &amp; E) stained section showed ductal structures (Figure&#xA0;
<xref rid="Fig2" ref-type="fig">2</xref>A). Immunohistochemistry was performed using standard procedures with monoclonal antibodies: 6&#xA0;F11 (Novacastra Laboratories Ltd., Burlingame, CA) for ER and 1A6 (Novacastra Laboratories Ltd., Burlingame) for PR and AB-8 monoclonal antibody (NeoMarker Lab Vision Co., Fremont, CA) for Her2, which proved negative for Her2neu and positive for Estrogen and Progesterone Receptors (Figure&#xA0;
<xref rid="Fig2" ref-type="fig">2</xref>B, C, D). The tumor was classified as a salivary duct carcinoma of the parotid gland. At this time, the patient had been receiving anastrozole as pseudo adjuvancy for two years without further evidence of disease (Figure&#xA0;
<xref rid="Fig1" ref-type="fig">1</xref>F).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Computed Tomography (CT). A</bold> CT showing solid lesion in right parotid gland (Baseline), <bold>B</bold> Stable Disease under tamoxifen treatment. <bold>C</bold> Growth of the solid lesion in right parotid, <bold>D</bold> Stable Disease after switch to anastrazol, <bold>E</bold> Postsurgical CT showing absence of right parotid gland <bold>F</bold> Stable disease in surveillance.</p></caption><graphic xlink:href="12885_2014_4895_Fig1_HTML" id="d30e434"/></fig><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Haematoxylin</bold>-<bold>eosin stain (H &amp; E) and Immunohistochemical studies. A</bold> Salivary Duct Carcinoma of Parotid Gland with cribriform growth pattern (H &amp; E), <bold>B</bold>. Her2/neu immunostaining showing negative membrane staining, <bold>C</bold> Positive Estrogen receptor immunostain, <bold>D</bold> Positive Progesterone receptor immunostain.</p></caption><graphic xlink:href="12885_2014_4895_Fig2_HTML" id="d30e458"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="conclusions">
      <title>Conclusions</title>
      <p>The histologic similarities between salivary duct carcinoma and ductal carcinoma of the breast in addition to the low response rates to chemotherapy have led to antihormonal therapies being considered for treatment. Salivary duct carcinomas responding to antiandrogen therapies and advanced adenoid cystic salivary tumors to Tamoxifen have been reported in the literature
[<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. However, Tamoxifen and Aromatase inhibitors (estrogen signaling inhibitor agents) have not been reported in the literature, due to the low expression of ER in Ductal Carcinoma of the Salivary Gland.</p>
      <p>Tamoxifen and anastrazole have proven to be effective in Ductal Carcinoma of the Breast and were considered a potential novel therapy in this case, stopping the progression of salivary gland carcinoma (SGC) and achieving long-term stability of ductal parotid carcinoma. Tamoxifen prevents the activation of estrogen responsive genes by inhibiting both translocation and nuclear binding of the receptor itself. Aromatase inhibitors like Anastrozole on the other hand prevent ER activation by inhibiting the conversion of androgens to estrogens by binding to the aromatase enzyme.</p>
      <p>Due to limited management options in salivary gland carcinoma and low rates of response to chemotherapy the goal of treatment for metastatic salivary gland carcinoma is palliation, since there is not strong evidence that survival is prolonged with systemic treatment. Targeted cancer therapies represent a promising strategy to treat these rare aggressive malignancies. Albeit, the expression of sex steroid hormone receptors in salivary gland carcinoma and the evidence of linking hormone receptors and growth factor receptors to the disease may lead to the use of hormone therapy in these specific cases. Estrogen receptor antagonists such as tamoxifen or aromatase inhibitors may represent a target for the establishment of a safe alternative therapy for SDC but more accurate data obtained from larger studies are required.</p>
      <p>Genetic profiling is a valuable approach to identify actionable mutations (BRAF or PIK3CA mutations) which could have a significant impact in this rare in highly aggressive malignancy.</p>
      <sec id="Sec4">
        <title>Consent</title>
        <p>Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-list>
          <def-item>
            <term>SDC</term>
            <def>
              <p>Salivary Ductal Carcinoma</p>
            </def>
          </def-item>
          <def-item>
            <term>EGFR</term>
            <def>
              <p>Epidermal growth factor receptor</p>
            </def>
          </def-item>
          <def-item>
            <term>ER</term>
            <def>
              <p>Estrogen Receptors</p>
            </def>
          </def-item>
          <def-item>
            <term>H &amp; E</term>
            <def>
              <p>Hematoxylin and Eosin</p>
            </def>
          </def-item>
          <def-item>
            <term>SGC</term>
            <def>
              <p>Salivary gland carcinoma.</p>
            </def>
          </def-item>
        </def-list>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contribution</bold>
        </p>
        <p>CS treated the patient, participated in conception, acquisition of data and drafting the article. FJ participated in drafting and revision. DR participated in histological examination of sample. CM participated in radiological examination of images. DP participated in critical review and supervision. All the authors read and approved the final paper.</p>
      </fn>
    </fn-group>
    <ack>
      <p>The authors wish to acknowledge the valuable contributions of Mrs. Elizabeth Guadarrama-Beltr&#xE1;n through her kindness and social work provided to this and many other patients at our institution. JH Flores-Arredondo, MD is currently supported by a National Institutes of Health (NIH) National Heart Lung and Blood Institute (NHLBI) T32 HL007812 training grant.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sung</surname>
              <given-names>M-W</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>J-W</given-names>
            </name>
            <name>
              <surname>Min</surname>
              <given-names>Y-G</given-names>
            </name>
            <name>
              <surname>Seong</surname>
              <given-names>W-J</given-names>
            </name>
            <name>
              <surname>Roh</surname>
              <given-names>J-L</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Kwon</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck</article-title>
          <source>Arch Otolaryngol Head Neck Surg</source>
          <year>2003</year>
          <volume>129</volume>
          <issue>11</issue>
          <fpage>1193</fpage>
          <lpage>1197</lpage>
          <pub-id pub-id-type="doi">10.1001/archotol.129.11.1193</pub-id>
          <pub-id pub-id-type="pmid">14623749</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Belsky</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Tachikawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cihak</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Salivary gland tumors in atomic bomb survivors, Hiroshima-Nagasaki, 1957 to 1970</article-title>
          <source>JAMA</source>
          <year>1972</year>
          <volume>219</volume>
          <issue>7</issue>
          <fpage>864</fpage>
          <lpage>868</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.1972.03190330034007</pub-id>
          <pub-id pub-id-type="pmid">5066669</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kleinsasser</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>H&#xFC;bner</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma</article-title>
          <source>Arch Klin Exp Ohren Nasen Kehlkopfheilkd</source>
          <year>1968</year>
          <volume>192</volume>
          <issue>1</issue>
          <fpage>100</fpage>
          <lpage>105</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00301495</pub-id>
          <pub-id pub-id-type="pmid">4301301</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seifert</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brocheriou</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cardesa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Eveson</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>WHO International Histological Classification of Tumours. Tentative Histological Classification of Salivary Gland Tumours</article-title>
          <source>Pathol Res Pract</source>
          <year>1990</year>
          <volume>186</volume>
          <issue>5</issue>
          <fpage>555</fpage>
          <lpage>581</lpage>
          <pub-id pub-id-type="doi">10.1016/S0344-0338(11)80220-7</pub-id>
          <pub-id pub-id-type="pmid">1962854</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murrah</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Batsakis</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Salivary duct carcinoma</article-title>
          <source>Ann Otol Rhinol Laryngol</source>
          <year>1994</year>
          <volume>103</volume>
          <issue>3</issue>
          <fpage>244</fpage>
          <lpage>247</lpage>
          <pub-id pub-id-type="doi">10.1177/000348949410300315</pub-id>
          <pub-id pub-id-type="pmid">8122843</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Madrigal</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>De Vicente</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Salivary duct carcinoma: an unusual case of long-term evolution</article-title>
          <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>
          <year>1999</year>
          <volume>88</volume>
          <issue>5</issue>
          <fpage>597</fpage>
          <lpage>602</lpage>
          <pub-id pub-id-type="doi">10.1016/S1079-2104(99)70092-2</pub-id>
          <pub-id pub-id-type="pmid">10556756</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guzzo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Di Palma</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Grandi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Molinari</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Salivary duct carcinoma: clinical characteristics and treatment strategies</article-title>
          <source>Head Neck</source>
          <year>1997</year>
          <volume>19</volume>
          <issue>2</issue>
          <fpage>126</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-0347(199703)19:2&lt;126::AID-HED7&gt;3.0.CO;2-6</pub-id>
          <pub-id pub-id-type="pmid">9059870</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nardi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Sadow</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Juric</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cosper</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Bergethon</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Scialabba</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Batten</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Borger</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Iafrate</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Heist</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Flaherty</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Bendell</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Deschler</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wirth</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Dias-Santagata</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment</article-title>
          <source>Clin Cancer Res</source>
          <year>2013</year>
          <volume>19</volume>
          <issue>2</issue>
          <fpage>480</fpage>
          <lpage>490</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1842</pub-id>
          <pub-id pub-id-type="pmid">23186780</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barnes</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Krause</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Contis</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Scalamogna</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature</article-title>
          <source>Oral Surg Oral Med Oral Pathol</source>
          <year>1994</year>
          <volume>78</volume>
          <issue>1</issue>
          <fpage>64</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="doi">10.1016/0030-4220(94)90119-8</pub-id>
          <pub-id pub-id-type="pmid">8078666</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jaspers</surname>
              <given-names>HCJ</given-names>
            </name>
            <name>
              <surname>Verbist</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Schoffelen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mattijssen</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Slootweg</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>van der Graaf</surname>
              <given-names>WTA</given-names>
            </name>
            <name>
              <surname>van Herpen</surname>
              <given-names>CML</given-names>
            </name>
          </person-group>
          <article-title>Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options</article-title>
          <source>J Clin Oncol</source>
          <year>2011</year>
          <volume>29</volume>
          <issue>16</issue>
          <fpage>e473</fpage>
          <lpage>e476</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2010.32.8351</pub-id>
          <pub-id pub-id-type="pmid">21422415</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Griffith</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Seethala</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Luvison</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chiosea</surname>
              <given-names>SI</given-names>
            </name>
          </person-group>
          <article-title>PIK3CA mutations and PTEN loss in salivary duct carcinomas</article-title>
          <source>Am J Surg Pathol</source>
          <year>2013</year>
          <volume>37</volume>
          <issue>8</issue>
          <fpage>1201</fpage>
          <lpage>1207</lpage>
          <pub-id pub-id-type="doi">10.1097/PAS.0b013e3182880d5a</pub-id>
          <pub-id pub-id-type="pmid">23851329</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cros</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sbidian</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Roussel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Scotte</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tartour</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Brasnu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Laurent-Puig</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bruneval</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Blons</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Badoual</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours</article-title>
          <source>Ann Oncol</source>
          <year>2013</year>
          <volume>24</volume>
          <issue>10</issue>
          <fpage>2624</fpage>
          <lpage>2629</lpage>
          <pub-id pub-id-type="doi">10.1093/annonc/mdt338</pub-id>
          <pub-id pub-id-type="pmid">23933559</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shadaba</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gaze</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Grant</surname>
              <given-names>HR</given-names>
            </name>
          </person-group>
          <article-title>The response of adenoid cystic carcinoma to tamoxifen</article-title>
          <source>J Laryngol Otol</source>
          <year>1997</year>
          <volume>111</volume>
          <issue>12</issue>
          <fpage>1186</fpage>
          <lpage>1189</lpage>
          <pub-id pub-id-type="doi">10.1017/S0022215100139684</pub-id>
          <pub-id pub-id-type="pmid">9509115</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van der Hulst</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>van Krieken</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>van der Kwast</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Gerritsen</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>de Jong RJ</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Nijeholt AA</surname>
              <given-names>L &#xE0;</given-names>
            </name>
            <name>
              <surname>Meinders</surname>
              <given-names>AE</given-names>
            </name>
          </person-group>
          <article-title>Partial remission of parotid gland carcinoma after goserelin</article-title>
          <source>Lancet</source>
          <year>1994</year>
          <volume>344</volume>
          <issue>8925</issue>
          <fpage>817</fpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(94)92372-8</pub-id>
          <pub-id pub-id-type="pmid">7521927</pub-id>
        </element-citation>
      </ref>
      <ref-list id="BSec1">
        <title>Pre-publication history</title>
        <ref id="CR15">
          <mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here:<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/14/701/prepub">http://www.biomedcentral.com/1471-2407/14/701/prepub</ext-link></mixed-citation>
        </ref>
      </ref-list>
    </ref-list>
  </back>
</article>
</pmc-articleset>
